New treatment options for late Na current, arrhythmias, and diastolic dysfunction.

Abstract

The late Na current is of pathophysiological importance for the heart. Ranolazine is an innovative anti-ischemic and antianginal agent that inhibits the late Na current, thereby reducing the Na-dependent Ca-overload, which improves diastolic tone and oxygen handling during myocardial ischemia. In addition, ranolazine seems to exert beneficial effects on diastolic cardiac function. Moreover, there are experimental and clinical data about its antiarrhythmic properties. A beneficial atrial selectivity of ranolazine has been suggested that may be helpful for the treatment of atrial fibrillation. The purpose of this review article is to discuss possible future clinical indications based on novel experimental and preclinical results and the significance of the available data.

• Authors: Lars S Maier
• Journal: Current heart failure reports (Curr Heart Fail Rep) Vol. 9 Issue 3 Pg. 183-91 (Sep 2012) ISSN: 1546-9549 [Electronic] United States
• PMID: 22767404 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Acetanilides
• Anti-Arrhythmia Agents
• Cardiovascular Agents
• Cations
• Enzyme Inhibitors
• NAV1.5 Voltage-Gated Sodium Channel
• Piperazines
• Sodium-Calcium Exchanger
• Sodium
• Ranolazine
• Calcium

Topics

• Acetanilides (therapeutic use)
• Action Potentials (drug effects)
• Anti-Arrhythmia Agents (therapeutic use)
• Arrhythmias, Cardiac (drug therapy)
• Atrial Fibrillation (drug therapy)
• Calcium (metabolism)
• Cardiovascular Agents (therapeutic use)
• Cations (metabolism)
• Diastole (drug effects)
• Enzyme Inhibitors (therapeutic use)
• Heart Failure (drug therapy)
• Heart Failure, Diastolic (drug therapy)
• Humans
• Myocardial Contraction (drug effects)
• NAV1.5 Voltage-Gated Sodium Channel (drug effects)
• Piperazines (therapeutic use)
• Ranolazine
• Sodium (metabolism)
• Sodium-Calcium Exchanger (drug effects)